Abstract Treatment resistance affects 20–60% of patients with psychiatric disorders; and is
associated with increased healthcare burden and costs up to ten-fold higher relative to …

Objective: Research and clinical translation in schizophrenia is limited by inconsistent
definitions of treatment resistance and response. To address this issue, the authors …

BackgroundClozapine remains the only evidence-based antipsychotic for treatment-
resistant schizophrenia (TRS). The ability to predict which patients with their first onset of …

Abstract Using Richardson and Davidson's model and the sciences of pharmacokinetics and
clinical pharmacopsychology, this article reviewed the:(1) poor life expectancy associated …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

Objective: Antipsychotic medication non-adherence has detrimental effects on patients'
clinical outcome. It is unclear which risk factors affect adherence most and which …

Objective Treatment resistance is a challenge for the management of schizophrenia. It is not
always clear whether inadequate response is secondary to medication ineffectiveness, as …

Background Minimal/non-response to antipsychotic treatment, and persistent positive
symptoms despite treatment, are common among patients with schizophrenia. The aim of …

Treatment-resistant schizophrenia, affecting approximately 20–30% of patients with
schizophrenia, has a high burden both for patients and healthcare services. There is a need …

Introduction Maintenance antipsychotic treatment improves multiple outcomes in people with
schizophrenia. These benefits are challenged by medication nonadherence, which is a …